| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-07-09 | Helsinn Healthcare (Switzerland) Advancell (Spain) | ATH008 | palmoplantar erythrodysesthesia syndrome, hand-foot skin reactions | development |
Cancer - Oncology - Dermatological diseases | Development agreement |
| 2013-07-09 | Cancer Research Technology (CRT) (UK) FORMA Therapeutics (USA) | cancer drugs targeting deubiquitinating enzymes (DUBs) | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-07-08 | Novartis (Switzerland) Biological E (India) | vaccines against typhoid and paratyphoid fever (Vi-CRM197) | typhoid fever, paratyphoid fever | development |
Infectious diseases | Development agreement |
| 2013-07-08 | Santaris Pharma (Denmark) RaNA Therapeutics (USA) | Locked Nucleic Acid (LNA) technology | undisclosed | licensing |
undisclosed | Licensing agreement |
| 2013-07-04 | UCB (Belgium) R-Pharm (Russia) | olokizumab | all indications, including rheumatoid arthritis | development |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Development agreement |
| 2013-07-04 | Debiopharm (Switzerland) Quartz Bio (Switzerland) | bioinformatics services | R&D |
Technology - Services | R&D agreement | |
| 2013-07-03 | Articzymes (Norway) GE Healthcare (USA) | products based on ArcticZymes’ unique heat-labile enzyme portfolio | supply |
Technology - Services | Services contract | |
| 2013-07-03 | Transgene (France) Ascend Biopharmaceuticals (Australia) | TG1042 | development |
Cancer - Oncology | Development agreement | |
| 2013-07-02 | BioInvent (Sweden) Mitsubishi Tanabe Pharma Corporation (Japan) | therapeutic antibodies from BioInvent\'s n-CoDeR® library | R&D |
Technology - Services | R&D agreement | |
| 2013-07-02 | Sirona Biochem (Canada) Biogalenys (France) | cell preservation technology | R&D |
R&D agreement | ||
| 2013-07-02 | Warp Drive Bio (USA - MA) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2013-07-01 | Pharming (The Netherlands) Shanghai Institute Of Pharmaceutical Industry (SIPI) (China) | Ruconest® (Rhucin® in non-European territories - conestat alfa) and Pharming\'s transgenic technology platform | collaboration |
Rare diseases - Genetic diseases | Collaboration agreement | |
| 2013-07-01 | MDX Health (Belgium) - Summit Pharmaceuticals International Corporation (SPI), a subsidiary of Sumitomo Corporation (Japan) | PharmacoMDx epigenetic technologies and products | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-07-01 | Autifony Therapeutics (UK) University of Manchester (UK) Newcastle University (UK) | novel, first-in-class Kv3 potassium channel modulator | schizophrenia | collaboration |
Mental diseases | Collaboration agreement |
| 2013-06-30 | UCB (Belgium) the Lieber Institute for Brain Development (LIBD) (USA) | novel lead compounds | cognitive impairment | R&D |
CNS diseases - Neurodegenerative diseases | R&D agreement |
| 2013-06-27 | PathoGenetix (USA) Applied Maths (Belgium) | integrated solution for rapid bacterial identification | collaboration |
Infectious diseases | Collaboration agreement | |
| 2013-06-27 | Karolinska Development (Sweden) Ospedale San Raffaele (Italy) Medical University of Graz (Austria) | collaboration |
Collaboration agreement | |||
| 2013-06-27 | Immunocore (UK) Genentech, a member of the Roche Group (USA - Switzerland) | novel cancer targets | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2013-06-27 | Vedanta Biosciences (USA - MA) Johnson & Johnson Innovation center, a J&J company (USA - NJ) | collaboration |
Autoimmune diseases - Inflammatory diseases - Infectious diseases | Collaboration agreement | ||
| 2013-06-26 | Nanobiotix (France) Nanotechnology Characterization Laboratory (NCL) (USA) | NBTX-IV | lung carcinoma, pancreatic cancer, brain metastasis | development |
Cancer - Oncology | Development agreement |
